Pilot clinical trial on the efficacy of prophylactic use of vitamin K 1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 13, Issue 1, 2014, Pages 62-67

  Pinta, Francesco ^a   Ponzetti, Agostino ^a   Spadi, Rosella ^a   Fanchini, Laura ^a   Zanini, Marcello ^a   Mecca, Caterina ^a   Sonetto, Cristina ^a   Ciuffreda, Libero ^a   Racca, Patrizia ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Acneiform rash; Cetuximab plus chemotherapy; Phytomenadione; Prevention; Topical treatment

Indexed keywords

ACNEIFORM RASH; CETUXIMAB PLUS CHEMOTHERAPY; PHYTOMENADIONE; PREVENTION; TOPICAL TREATMENT;

ADMINISTRATION, CUTANEOUS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EXANTHEMA; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; PILOT PROJECTS; SKIN CREAM; VITAMIN K 1;

EID: 84895074194     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.10.001     Document Type: Article

References (39)

1. G. Folprecht, T. Gruenberger, and W.O. Bechstein et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 2004 38 47
2. L.B. Saltz, N.J. Meropol, and P.J. Loehrer et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
3. D. Cunningham, Y. Humblet, and S. Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
4. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis et al. Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
5. A.F. Sobrero, J. Maurel, and L. Fehrenbacher et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
6. H.J. Lenz, E. Van Cutsem, and S. Khambata-Ford et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 2006 4914 4921
7. E. Van Cutsem, C.H. Kohne, and E. Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
8. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
9. T.S. Maughan, R.A. Adams, and C.G. Smith et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
10. L.I. Wagner, and M.E. Lacouture Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae Oncology (Williston Park) 21 2007 34 36
11. T. Li, and R. Perez-Soler Skin toxicities associated with epidermal growth factor receptor inhibitors Target Oncol 4 2009 107 119
12. F. Romito, F. Giuliani, and C. Cormio et al. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients Support Care Cancer 18 2010 329 334
13. S.S. Joshi, S. Ortiz, and J.N. Witherspoon et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life Cancer 116 2010 3916 3923
14. I. Lang, C.H. Kohne, and G. Folprecht et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin Eur J Cancer 49 2012 439 448
15. A.L. Agero, S.W. Dusza, and C. Benvenuto-Andrade et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 2006 657 670
16. A. Jatoi, E.M. Green, and K.M. Rowland et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group study N0147 Oncology 77 2009 120 123
17. X. Su, M.E. Lacouture, and Y. Jia et al. Risk of high-grade skin rash in cancer patients treated with cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis Oncology 77 2009 124 133
18. M. Orditura, F. De Vita, and G. Galizia et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis Oncol Rep 21 2009 1023 1028
19. E. Van Cutsem, D. Teipar, and D. Vanbeckevoort et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reaction: the randomized EVEREST study J Clin Oncol 30 2012 2861 2868
20. C. Pinto, C.A. Barone, and G. Girolomoni et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy Oncologist 16 2011 228 238
21. C.R. Garrett, and C. Eng Cetuximab in the treatment of patients with colorectal cancer Expert Opin Biol Ther 11 2011 937 949
22. A. Scope, A.L. Agero, and S.W. Dusza et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption J Clin Oncol 25 2007 5390 5396
23. A. Jatoi, K. Rowland, and J.A. Sloan et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB) Cancer 113 2008 847 853
24. M.E. Lacouture, E.P. Mitchell, and B. Piperdi et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
25. A. Du-Thanh, N. Kluger, and H. Bensalleh et al. Drug-induced acneiform eruption Am J Clin Dermatol 12 2011 233 245
26. C.A. DeWitt, A.E. Siroy, and S.P. Stone Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy J Am Acad Dermatol 56 2007 500 505
27. S. Pastore, F. Mascia, and V. Mariani et al. The epidermal growth factor receptor system in skin repair and inflammation J Invest Dermatol 128 2008 1365 1374
28. K. Potthoff, R. Hofheinz, and J.C. Hassel et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion Ann Oncol 22 2010 524 535
29. V.V. Vintonyak, A.P. Antonchick, and D. Rauh et al. The therapeutic potential of phosphatase inhibitors Curr Opin Chem Biol 13 2009 272 283
30. R. Perez-Soler, Y. Zou, and T. Li et al. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin ASCO Annual Meeting Proceedings 2006 abstract 3036
31. R. Perez-Soler, Y. Zou, and T. Li et al. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab Clin Cancer Res 17 2011 6766 6777
32. R. Perez-Soler, Y. Zou, and T. Li et al. Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib in human keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of skin rash ASCO Annual Meeting Proceedings 2007 abstract 9124
33. H. Tomkova, M. Pospiskova, and M. Zabojnikova et al. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis J Eur Acad Dermatol Venereol 27 2013 514 519
34. J. Ocvirk, and S. Cencelj Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer J Eur Acad Dermatol Venereol 24 2010 453 459
35. 1 cream ASCO Annual Meeting Proceedings 2009 abstract e15087
36. 1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: first analysis of an observational Italian study Gastrointestinal Cancers Symposium 2011 abstract
37. 1 cream on cetuximab-induced acne-like rash ASCO Annual Meeting Proceedings 2010 abstract e19671
38. Common Terminology Criteria for Adverse Events, version 3.0. Available at: ctep.cancer.gov/reporting/ctc.html. Accessed: September 21, 2013.
39. P. Racca, L. Fanchini, and V. Caliendo et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation Clin Colorectal Cancer 7 2008 48 54